Envista Announces Pricing of $430 Million of Senior Notes

Impact · against what's priced in

Envista's debt refinancing is a neutral-to-slightly-positive capital structure move that reduces immediate liquidity risk but adds fixed interest expense. For the bookrunning banks, the fees from a $430 million offering are immaterial relative to their massive revenue and earnings expectations.

BAC+0.00: Doesn't touch the price's assumptions
The price assumes: A continuation of current consumer banking, wealth management, and global banking revenue near $191.6 billion

Envista Announces Pricing of $430 Million of Senior Notes

What matters in this story

TransMedics: 2027 Setting Up To Be A Pivotal Year

Envista Announces Pricing of $430 Million of Senior Notes

What matters in this story

TransMedics: 2027 Setting Up To Be A Pivotal Year

How each ticker is affected

Connected tickers

Track these names every morning.

AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline

PHC Holdings Corporation (PHCCF) Q2 2027 Earnings Call Transcript

FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track

Village Farms Well Positioned For Entry Into Texas Cannabis Markets (Rating Upgrade)

Envista Announces Pricing of $430 Million of Senior Notes

What matters in this story

Next reads from the same story arc

TransMedics: 2027 Setting Up To Be A Pivotal Year

Envista Announces Pricing of $430 Million of Senior Notes

What matters in this story

Next reads from the same story arc

TransMedics: 2027 Setting Up To Be A Pivotal Year

How each ticker is affected

Connected tickers

Track these names every morning.

AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline

PHC Holdings Corporation (PHCCF) Q2 2027 Earnings Call Transcript

FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track

Village Farms Well Positioned For Entry Into Texas Cannabis Markets (Rating Upgrade)